Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 8.9%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares traded down 8.9% during mid-day trading on Wednesday . The company traded as low as $21.31 and last traded at $21.33. 134,878 shares traded hands during trading, a decline of 7% from the average session volume of 145,499 shares. The stock had previously closed at $23.42.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DNTH. Stifel Nicolaus started coverage on Dianthus Therapeutics in a research note on Thursday, February 15th. They set a "buy" rating and a $44.00 target price on the stock. Raymond James boosted their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an "outperform" rating in a research note on Thursday, April 18th. Wedbush upped their price target on Dianthus Therapeutics from $24.00 to $33.00 and gave the company an "outperform" rating in a research report on Friday, March 22nd. Finally, Jefferies Financial Group upped their price target on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a "buy" rating in a research report on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $42.40.

Dianthus Therapeutics Stock Performance

The business has a fifty day moving average of $25.82 and a 200 day moving average of $17.45.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($0.71) EPS for the quarter, beating analysts' consensus estimates of ($1.11) by $0.40. The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.73 million. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. FMR LLC bought a new position in Dianthus Therapeutics in the third quarter worth $28,961,000. Avidity Partners Management LP purchased a new stake in shares of Dianthus Therapeutics during the third quarter valued at $16,644,000. Octagon Capital Advisors LP boosted its position in shares of Dianthus Therapeutics by 15.4% during the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company's stock valued at $5,762,000 after buying an additional 74,000 shares during the last quarter. Atlas Venture Life Science Advisors LLC purchased a new position in Dianthus Therapeutics in the third quarter worth about $3,240,000. Finally, Vestal Point Capital LP purchased a new position in Dianthus Therapeutics in the fourth quarter worth about $1,404,000. Institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.